Neurogene (NGNE) Amortizatization of Intangibles (2019 - 2026)
Neurogene (NGNE) reported Amortizatization of Intangibles of $374000.0 for Q1 2026, up 2776.92% on a YoY basis from $13000.0 in Q1 2025, and down 91.69% quarter-over-quarter from $4.5 million in Q4 2025.
Neurogene (NGNE) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Neurogene has reported Amortizatization of Intangibles for 8 years, with the latest figure at $374000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 2776.92% year-over-year to $374000.0; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 8801.82% YoY), and the FY2025 full-year result was $4.5 million, up 8623.08% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $374000.0, down from $4.5 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $4.5 million in Q4 2025, with the low at -$772000.0 in Q4 2022.
- Historically, Amortizatization of Intangibles has averaged $363600.0 across 5 years, with a median of $13000.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles slumped 420.33% — and 2025, when it soared 34500.0%.
- Neurogene's Amortizatization of Intangibles stood at -$772000.0 in 2022, then jumped by 104.53% to $35000.0 in 2023, then tumbled by 62.86% to $13000.0 in 2024, then soared by 34500.0% to $4.5 million in 2025, then tumbled by 91.69% to $374000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $374000.0 (Q1 2026), $4.5 million (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | 374,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 374,000.00 |
| Mar 31, 2026 | 374,000.00 |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 446,000.00 |
| Mar 31, 2024 | 446,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Dec 31, 2023 | 35,000.00 |